Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT02583438
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT02583438
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT02583438. Allocation not applicable; no masking; primary purpose treatment. Start 2015-10 (registry gives no type); primary completion 2017-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Condition
- Obesity
- Intervention (Drug)
- Saxagliptin (Bristol-Myers Squibb Company)
- Lead sponsor
- Beijing Chao Yang Hospital
Record details
- Record id
cardio:ct-nct02583438- Content hash
3e51b60d02497d2e3caf90838ccae729433716559478743586bc5596a0a09195